Does Rallies show 13F holders for UTHR?

Yes. Rallies tracks hedge fund and 13F ownership data for UTHR, including fund names, share counts, latest tracked quarter, and position changes when available.

Is UTHR research on Rallies investment advice?

No. Rallies provides research, data, and educational context for UTHR. It does not provide personalized investment advice.

UTHR (United Therapeutics) Stock Analysis - Hedge Fund Holdings

United Therapeutics (UTHR) is a publicly traded Healthcare sector company. As of May 21, 2026, UTHR trades at $562.26 with a market cap of $24.07B and a P/E ratio of 19.26. UTHR moved -0.44% today. Year to date, UTHR is +15.16%; over the trailing twelve months it is +82.17%. Its 52-week range spans $266.98 to $609.35. Analyst consensus is strong buy with an average price target of $647.83. Rallies surfaces UTHR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns UTHR stock?

Hedge funds tracked by Rallies that own UTHR include Bridgewater Associates, Orbimed Advisors, Panagora Asset, Pinebridge Investments, and Eisler Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for United Therapeutics.

UTHR Key Metrics

Key financial metrics for UTHR
Metric	Value
Price	$562.26
Market Cap	$24.07B
P/E Ratio	19.26
EPS	$29.27
Dividend Yield	0.00%
52-Week High	$609.35
52-Week Low	$266.98
Volume	8
Avg Volume	0
Revenue (TTM)	$3.17B
Net Income	$1.29B
Gross Margin	86.58%

Top Hedge Funds Holding UTHR

Bridgewater Associates holds 111.17K shares of UTHR, changed +72.10% as of Mar 31, 2026.
Orbimed Advisors holds 105.20K shares of UTHR, changed -8.44% as of Dec 31, 2025.
Panagora Asset holds 34.95K shares of UTHR, changed +3124.45% as of Mar 31, 2026.
Pinebridge Investments holds 11.31K shares of UTHR, changed -37.67% as of Sep 30, 2025.
Eisler Capital holds 3.64K shares of UTHR, changed -46.43% as of Mar 31, 2024.

Latest UTHR News

United Therapeutics slides despite same-day Wells Fargo upgrade after Q1 results digestion — May 7, 2026
United Therapeutics jumps as Q1 results spotlight ralinepag DPI plans and trial momentum — May 6, 2026
United Therapeutics rises as ralinepag Phase 3 win and $2B buyback support shares — Apr 8, 2026
United Therapeutics falls as traders lock in gains after TETON-1-driven surge — Apr 2, 2026
United Therapeutics dips 3% as investors lock in gains after March catalysts — Apr 1, 2026

Recent UTHR Insider Trades

ROTHBLATT MARTINE A sold 1.48K (~$836.26K) on May 15, 2026.
ROTHBLATT MARTINE A sold 1.87K (~$1.06M) on May 15, 2026.
ROTHBLATT MARTINE A sold 3.21K (~$1.82M) on May 15, 2026.

UTHR Analyst Consensus

13 analysts cover UTHR: 0 strong buy, 10 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $647.83.

Common questions about UTHR

Who owns UTHR stock?: Hedge funds tracked by Rallies that own UTHR include Bridgewater Associates, Orbimed Advisors, Panagora Asset, Pinebridge Investments, and Eisler Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for United Therapeutics.
Does Rallies show 13F holders for UTHR?: Yes. Rallies tracks hedge fund and 13F ownership data for UTHR, including fund names, share counts, latest tracked quarter, and position changes when available.
Is UTHR research on Rallies investment advice?: No. Rallies provides research, data, and educational context for UTHR. It does not provide personalized investment advice.